GERN Geron Corporation Stock Quote

GERN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	0.10%	Shs Outstand	332.07M	Perf Week	-0.92%
Market Cap	707.95M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.00%	Shs Float	-	Perf Month	16.85%
Income	-118.40M	PEG	-	EPS next Q	-0.10	Inst Own	49.40%	Short Float	-	Perf Quarter	51.41%
Sales	1.40M	P/S	505.68	EPS this Y	-27.20%	Inst Trans	0.08%	Short Ratio	5.30	Perf Half Y	102.83%
Book/sh	0.29	P/B	7.41	EPS next Y	0.00%	ROA	-51.30%	Target Price	4.20	Perf Year	67.97%
Cash/sh	0.51	P/C	4.25	EPS next 5Y	5.00%	ROE	-84.20%	52W Range	0.99 - 2.67	Perf YTD	76.23%
Dividend	-	P/FCF	-	EPS past 5Y	-13.80%	ROI	-64.70%	52W High	-21.21%	Beta	0.93
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-25.70%	Gross Margin	-	52W Low	112.52%	ATR	0.18
Employees	69	Current Ratio	3.80	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	52.58	Volatility	8.98% 8.77%
Optionable	Yes	Debt/Eq	0.51	EPS Q/Q	-5.40%	Profit Margin	-	Rel Volume	0.80	Prev Close	2.15
Shortable	Yes	LT Debt/Eq	0.51	Earnings	Aug 11 AMC	Payout	-	Avg Volume	3.05M	Price	2.10
Recom	1.60	SMA20	1.07%	SMA50	18.79%	SMA200	48.10%	Volume	863,207	Change	-2.15%

Jul-28-22

Resumed

B. Riley Securities

Buy

Nov-02-21

Initiated

Robert W. Baird

Outperform

Feb-18-21

Resumed

B. Riley Securities

Buy

Aug-03-20

Initiated

Stifel

Buy

Nov-19-19

Resumed

B. Riley FBR

Buy

Sep-03-19

Initiated

H.C. Wainwright

Buy

Aug-15-19

Initiated

Cantor Fitzgerald

Overweight

Apr-09-19

Upgrade

Needham

Hold → Buy

Jan-31-19

Upgrade

B. Riley FBR

Neutral → Buy

$1.50 → $3.25

Oct-02-18

Downgrade

B. Riley FBR

Buy → Neutral

$5.75 → $1.50

Jul-05-18

Initiated

B. Riley FBR, Inc.

Buy

$5.75

Sep-13-16

Reiterated

FBR Capital

Outperform

$6 → $5

Sep-13-16

Reiterated

FBR & Co.

Outperform

$6 → $5

Dec-07-15

Reiterated

Piper Jaffray

Overweight

$5 → $10

Apr-21-15

Initiated

Oppenheimer

Outperform

$5.50

Jun-12-14

Upgrade

MLV & Co

Hold → Buy

$2 → $4.25

Mar-12-14

Downgrade

MLV & Co

Buy → Hold

$9 → $2

Dec-10-13

Upgrade

Needham

Hold → Buy

$10

Dec-10-13

Reiterated

MLV & Co

Buy

$8 → $9

Nov-08-13

Reiterated

MLV & Co

Buy

$6.50 → $8

Aug-12-22 11:21AM	J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023 Zacks +14.63%
Aug-11-22 11:00PM	Geron (GERN) Q2 2022 Earnings Call Transcript Motley Fool -5.53%
05:24PM	Small Caps Begin to Rebound: 10 Stocks to Buy Now Insider Monkey
04:05PM	Geron Corporation Reports Second Quarter 2022 Financial Results Business Wire
01:27PM	Top Penny Stocks for August 2022 Investopedia
Aug-10-22 02:54PM	Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well Zacks
Aug-09-22 12:14PM	Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat Zacks -7.59%
12:03PM	Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data Zacks
Aug-04-22 04:30PM	Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022 Business Wire +20.59%
12:00PM	All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy Zacks
Aug-03-22 04:30PM	Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference Business Wire +5.15%
Jul-21-22 07:05PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-13-22 10:18AM	7 Best Penny Stocks Under $3 to Buy in July InvestorPlace
Jul-08-22 11:44AM	VERU's Shares Jump on Successful COVID-19 Study Results Zacks
Jul-07-22 11:30AM	Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies Zacks +5.91%
Jul-01-22 11:01AM	Novartis (NVS) Announces Positive Data on Oncology Drug Zacks +7.74%
Jun-30-22 04:15PM	Geron Corporation Announces Expansion of Existing Loan Facility Business Wire
Jun-29-22 10:28AM	Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma Zacks
Jun-28-22 08:49AM	Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA Zacks +6.38%
Jun-27-22 01:21PM	Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation Zacks
01:06PM	Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion Zacks
Jun-24-22 12:30PM	Gilead (GILD) Announces Positive Data on Hepcludex for HDV Zacks
Jun-17-22 11:31AM	Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies Zacks
09:36AM	Bausch (BHC) Suspends IPO Plans for Solta Medical Zacks
Jun-16-22 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire -8.46%
12:15PM	Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints Zacks
Jun-15-22 04:10PM	Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role Business Wire
Jun-13-22 06:13AM	Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health Zacks -5.19%
Jun-10-22 11:57AM	4 Biotech Stocks With Bright Prospects to Buy Amid Recovery Zacks
09:40AM	Has Geron (GERN) Outpaced Other Medical Stocks This Year? Zacks
Jun-08-22 11:45AM	Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib Zacks
May-31-22 09:21AM	Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet? Simply Wall St.
May-30-22 03:10PM	Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah Zacks
03:03PM	Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC Zacks
May-23-22 12:26PM	Regeneron's (REGN) Evkeeza Positive in Late-Stage Study Zacks
11:46AM	Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA Zacks
May-19-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:15PM	Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt Zacks
May-17-22 04:30PM	Geron to Present at the H.C. Wainwright Global Investment Conference Business Wire
11:33AM	Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints Zacks
11:30AM	Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold Zacks
May-10-22 12:21PM	Why Geron Stock Is Soaring Today Motley Fool +20.33%
02:09AM	Geron (GERN) Q1 2022 Earnings Call Transcript Motley Fool
May-09-22 05:55PM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates Zacks -5.38%
04:05PM	Geron Corporation Reports First Quarter 2022 Financial Results Business Wire
May-02-22 04:30PM	Geron to Announce First Quarter 2022 Financial Results on May 9, 2022 Business Wire +5.67%
May-01-22 08:39AM	Shareholders in Geron (NASDAQ:GERN) are in the red if they invested five years ago Simply Wall St.
Apr-21-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-07-22 05:51AM	3 of the Fastest-Growing Stocks on the Planet Through 2026 Motley Fool
Apr-06-22 04:30PM	Geron to Present at the 21st Annual Needham Virtual Healthcare Conference Business Wire +5.77%
Apr-01-22 04:15PM	Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants Business Wire +11.76%
Mar-30-22 05:24PM	Why Geron's Shares Rose 23.4% on Wednesday Motley Fool +25.00%
02:25AM	Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants Business Wire
Mar-29-22 04:01PM	Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants Business Wire +5.79%
Mar-17-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +13.59%
Mar-10-22 09:00PM	Geron (GERN) Q4 2021 Earnings Call Transcript Motley Fool
04:06PM	Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones Business Wire
Mar-03-22 04:30PM	Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 Business Wire
Jan-31-22 10:18AM	Could The Geron Corporation (NASDAQ:GERN) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jan-26-22 10:05AM	Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS Zacks
Jan-21-22 07:30AM	Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference Business Wire
Jan-20-22 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-04-22 05:01PM	Geron to Present at the H.C. Wainwright BioConnect Conference Business Wire -6.11%
Dec-16-21 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-14-21 04:30PM	Geron Reports Presentations at American Society of Hematology Annual Meeting Business Wire
Dec-02-21 07:30AM	Geron Announces Appointment of Chief Business Officer Business Wire
Nov-18-21 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-12-21 07:30AM	Geron to Present at the Stifel 2021 Virtual Healthcare Conference Business Wire
Nov-09-21 09:05PM	Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:00PM	Geron Presents Investor Event Highlights Business Wire
Nov-04-21 09:12AM	Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting Business Wire
Oct-31-21 10:44AM	Is Geron (NASDAQ:GERN) Using Debt In A Risky Way? Simply Wall St.
Oct-28-21 03:06PM	Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for Zacks +8.28%
Oct-25-21 04:30PM	Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat Business Wire
Oct-21-21 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-18-21 07:30AM	Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes Business Wire
Oct-15-21 04:05PM	Geron to Host a Virtual Investor Event in November Business Wire
Oct-11-21 04:30PM	Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology Business Wire
Sep-16-21 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-01-21 04:30PM	Geron Announces September Investor Conference Presentation Webcasts Business Wire
Aug-28-21 08:01AM	Here's What Investors Need From Geron Motley Fool
Aug-19-21 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-17-21 08:28AM	The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga +6.67%
05:00AM	Geron (GERN) Q2 2021 Earnings Call Transcript Motley Fool
Aug-16-21 05:25PM	Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:06PM	Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023 Business Wire
Aug-05-21 04:30PM	Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021 Business Wire
Aug-02-21 06:09AM	Do Institutions Own Geron Corporation (NASDAQ:GERN) Shares? Simply Wall St.
Jul-29-21 03:05PM	Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline Zacks -5.38%
Jul-22-21 04:45PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-21-21 12:15PM	Geron (GERN) Soars on Imetelstat Data for Myelofibrosis Zacks -7.10%
08:36AM	Do Options Traders Know Something About Geron (GERN) Stock We Don't? Zacks
Jun-18-21 11:40AM	Why Geron Stock Is Soaring Today Motley Fool +29.79%
10:04AM	Geron Skyrockets on Bone Marrow Cancer Treatment Trial TheStreet.com
06:31AM	Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In Journal Benzinga
Jun-17-21 04:30PM	Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology Business Wire
Jun-14-21 04:30PM	Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress Business Wire
May-12-21 10:56AM	Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress Business Wire
May-11-21 02:01AM	Geron (GERN) Q1 2021 Earnings Call Transcript Motley Fool +11.20%
May-10-21 05:55PM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates Zacks -6.02%

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 20	Option Exercise	1.41	35,000	49,350	74,047	Apr 21 08:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience